The primary objective of this study is to evaluate the efficacy of safety of etanercept dose
reduction combined with sulfasalazine in ankylosing spondylitis (AS) patients who have
achieved a significant clinical response.
Drug: etanercept (Half-Dose)
Drug: etanercept (Full-Dose)
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02638896
Ages eligible for Study
18 Years to 45 Years
Genders eligible for Study
Accepts Healthy Volunteers
Patients 18 to 45 years of age.
Proven AS according to the modified New York criteria
Negative result of a pregnancy test in serum in screening visit and in urine in baseline visit, done in all women, except those surgically sterilized and those who have at least one year of menopause.
Sexually active women of childbearing potential must agree and commit to use a medically accepted form of contraception.
ASDAS score ≥2.1
Ability to reconstitute the drug and self-inject it or have a person who can do so.
Capability to understand and voluntarily give written informed consent that is signed and dated, before any specific procedure of the protocol is performed.
Ability to store injectable test article at 2º to 8º C.
Previously exposure to murine or chimeric monoclonal antibodies.
Receipt of any live (attenuated) vaccines within 4 weeks before screening visit.
History of chronic or a recent serious infection.
History of tuberculosis within the last 3 years.
History of malignancy.
Significant concurrent medical diseases including uncompensated congestive heart failure, myocardial infarction within 12 months, stable or unstable angina pectoris, uncontrolled hypertension, severe pulmonary disease, history of human immunodeficiency virus (HIV) infection, central nervous system demyelinating events suggestive of multiple sclerosis.
Presence or history of confirmed blood dyscrasias.
History of any viral hepatitis within 1 year prior screening or history of any drug-induced liver injury at any time prior to screening.
Laboratory exclusions are: hemoglobin level < 8.5 mg/dl white blood cell count < 3.5×10e9/l, platelet count < 125 ×10e9/l, creatinine level > 175 mcmol/l, liver enzymes > 1.5 times the upper limit of normal or alkaline phosphatase > 2 times the upper limit of normal.
Participation in trials of other investigational medications within 30 days of entering the study.
Clinical examination showing significant abnormalities of clinical relevance.
Concomitant medication with disease-modifying anti-rheumatic drugs (DMARDs) or corticosteroids.
Hypersensitivity to any regent of study.
All locations for NCT02638896
View full eligibility
Tris trial is registered with FDA with number: NCT02638896. The sponsor of the trial is Zhixiang Huang and it is looking for 100 volunteers for the current phase.
Official trial title: Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.